Key statistics
On Friday, 89Bio Inc (ETNB:NMQ) closed at 8.19, 24.56% above the 52 week low of 6.58 set on Oct 23, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.29 |
---|---|
High | 8.34 |
Low | 8.07 |
Bid | 7.98 |
Offer | 9.05 |
Previous close | 8.29 |
Average volume | 547.49k |
---|---|
Shares outstanding | 105.91m |
Free float | 105.20m |
P/E (TTM) | -- |
Market cap | 867.40m USD |
EPS (TTM) | -1.97 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
- 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer
- 89bio to Participate in Upcoming Investor Conferences
- 89bio Appoints Francis Sarena as Chief Operating Officer
- 89bio Reports Second Quarter 2024 Financial Results and Corporate Updates
- 89bio Appoints Charles McWherter, Ph.D., to its Board of Directors
- 89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
- 89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
- 89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
- 89bio to Participate in the BofA Securities 2024 Health Care Conference
More ▼